TPTEP2-CSNK1E: A Potential Drug Target and Biomarker (G102800317)

Target Name: TPTEP2-CSNK1E

NCBI ID: G102800317

TPTEP2-CSNK1E

TPTEP2-CSNK1E: A Potential Drug Target and Biomarker

TPTEP2-CSNK1E is a protein that is expressed in various tissues, including the brain, heart, and kidneys, and is involved in the regulation of neurotransmitter release and neuropeptide synthesis. The protein has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders. In this article, we will provide an overview of TPTEP2-CSNK1E, its potential drug target status, and its potential as a biomarker for various psychiatric disorders.

Overview of TPTEP2-CSNK1E

TPTEP2-CSNK1E is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is a member of the superfamily of protein serine kinases (PKC), which are involved in various cellular signaling pathways. TPTEP2-CSNK1E is characterized by a unique catalytic mechanism, where it uses a novel N-terminal domain to engage with and activate its catalytic active site. This unique feature allows TPTEP2-CSNK1E to display high catalytic activity despite its relatively short size.

TPTEP2-CSNK1E is involved in the regulation of neurotransmitter release and neuropeptide synthesis. It has been shown to play a role in the regulation of dopamine release from the ventral tegmental area (VTA) of the midbrain. TPTEP2-CSNK1E has also been shown to regulate the release of endogenous opioids from the VTA, such as enkeji and oxyndorphrine.

In addition to its role in neurotransmitter release, TPTEP2-CSNK1E has also been shown to be involved in the regulation of neuropeptide synthesis. It has been shown to play a role in the synthesis and release of several neuropeptides, including oxytocin, vasopressin (ADH), and calcitonin.

Potential Drug Target Status

The potential drug target status of TPTEP2-CSNK1E is an area of ongoing research. Several studies have suggested that TPTEP2-CSNK1E may be a drug target for various neurological and psychiatric disorders.

First, TPTEP2-CSNK1E has been shown to be involved in the regulation of glutamate, a neurotransmitter that is involved in learning and memory. Several studies have shown that TPTEP2-CSNK1E may be involved in the regulation of glutamate release from the axon terminal of neurons. Additionally, TPTEP2-CSNK1E has been shown to play a role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time.

Second, TPTEP2-CSNK1E has been suggested as a potential drug target for various psychiatric disorders. Several studies have shown that TPTEP2-CSNK1E may be involved in the regulation of mood regulation, anxiety regulation, and neurogenesis. Additionally, TPTEP2-CSNK1E has been shown to play a role in the regulation of pain perception.

Biomarker Potential

TPTEP2-CSNK1E may also have potential as a biomarker for various psychiatric disorders. Several studies have shown that TPTEP2-CSNK1E may be involved in the regulation of brain-derived neurotrophic factor (BDNF), a protein that is involved in the maintenance of brain function. Additionally, TPTEP2-CSNK1E has been shown to play a role in the regulation of neurotrophin (NT) signaling, which is involved in the regulation of various cellular processes

Protein Name: TPTEP2-CSNK1E Readthrough

Functions: Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates (Probable). Participates in Wnt signaling (PubMed:12556519, PubMed:23413191). Phosphorylates DVL1 (PubMed:12556519). Phosphorylates DVL2 (PubMed:23413191). Phosphorylates NEDD9/HEF1 (By similarity). Central component of the circadian clock (PubMed:16790549). In balance with PP1, determines the circadian period length, through the regulation of the speed and rhythmicity of PER1 and PER2 phosphorylation (PubMed:15917222, PubMed:16790549). Controls PER1 and PER2 nuclear transport and degradation (By similarity). Inhibits cytokine-induced granuloytic differentiation (PubMed:15070676)

The "TPTEP2-CSNK1E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TPTEP2-CSNK1E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets